{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:53:36Z","timestamp":1769111616590,"version":"3.49.0"},"reference-count":44,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1253\/circj.cj-15-0783","type":"journal-article","created":{"date-parts":[[2015,12,6]],"date-time":"2015-12-06T17:04:11Z","timestamp":1449421451000},"page":"157-167","source":"Crossref","is-referenced-by-count":27,"title":["Prognostic Impact of New-Onset Atrial Fibrillation in Patients With Chronic Heart Failure\u3000\u2013 A Report From the CHART-2 Study \u2013"],"prefix":"10.1253","volume":"80","author":[{"given":"Takeshi","family":"Yamauchi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"},{"name":"Department of Evidence-Based Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Tadaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Ushigome","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Onose","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruri","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Nochioka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Evidence-Based Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"},{"name":"Department of Evidence-Based Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the CHART-2 Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. <i>Am J Cardiol<\/i> 2003; 91(Suppl): 2D\u20138D.","DOI":"10.1016\/S0002-9149(02)03373-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Benjamin EJ, Levy D, Vaziri SM, D\u2019Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham heart study. <i>JAMA<\/i> 1994; 271: 840\u2013844.","DOI":"10.1001\/jama.1994.03510350050036"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: A study of 390 patients. <i>Circulation<\/i> 1991; 84: 40\u201348.","DOI":"10.1161\/01.CIR.84.1.40"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: Results from COMET. <i>Eur Heart J<\/i> 2005; 26: 1303\u20131308.","DOI":"10.1093\/eurheartj\/ehi166"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rusinaru D, Leborgne L, Peltier M, Tribouilloy C. Effect of atrial fibrillation on long-term survival in patients hospitalized for heart failure with preserved ejection fraction. <i>Eur J Heart Fail<\/i> 2008; 10: 566\u2013572.","DOI":"10.1016\/j.ejheart.2008.04.002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Dries DL, Exner DV, Gersh BJ, Domansuki MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. <i>J Am Coll Cardiol<\/i> 1998; 32: 695\u2013703.","DOI":"10.1016\/S0735-1097(98)00297-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kober L, Swedberg K, McMurray JJV, Pfeffer MA, Velazquez EJ, Diaz R, et al. Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>Eur J Heart Fail<\/i> 2006; 8: 591\u2013598.","DOI":"10.1016\/j.ejheart.2005.11.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>J Am Coll Cardiol<\/i> 2006; 47: 1997\u20132004.","DOI":"10.1016\/j.jacc.2006.01.060"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hamaguchi S, Yokoshiki H, Kinugawa S, Tsuchihashi M, Yokota T, Takeshita A, et al. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: A report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). <i>Circ J<\/i> 2009; 73: 2084\u20132090.","DOI":"10.1253\/circj.CJ-09-0316"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. <i>J Am Coll Cardiol<\/i> 1996; 28: 1458\u20131463.","DOI":"10.1016\/S0735-1097(96)00358-0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: Results of the COoperative North Scandinavian ENalapril SUrvival Study (CONSENSUS). <i>N Engl J Med<\/i> 1987; 316: 1429\u20131435.","DOI":"10.1056\/NEJM198706043162301"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Morris JJ, Entman M, North WC, Kong Y, McIntosh H. The changes in cardiac output with reversion of atrial fibrillation to sinus rhythm. <i>Circulation<\/i> 1965; 31: 670\u2013678.","DOI":"10.1161\/01.CIR.31.5.670"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. <i>J Am Coll Cardiol<\/i> 1998; 32: 197\u2013204.","DOI":"10.1016\/S0735-1097(98)00221-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Creland JGF, et al. Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: An individual-patient data meta-analysis. <i>Lancet<\/i> 2014; 384: 2235\u20132243.","DOI":"10.1016\/S0140-6736(14)61373-8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: The Framingham study. <i>Am Heart J<\/i> 1983; 106: 389\u2013396.","DOI":"10.1016\/0002-8703(83)90208-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. <i>Circ J<\/i> 2014; 78: 1997\u20132021.","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. <i>Am J Cardiol<\/i> 2013; 112: 1142\u20131147.","DOI":"10.1016\/j.amjcard.2013.05.063"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham study. <i>J Am Coll Cardiol<\/i> 1993; 22(Suppl A): 6A\u201313A.","DOI":"10.1016\/0735-1097(93)90455-A"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure. <i>J Am Coll Cardiol<\/i> 2014; 63: 1123\u20131133.","DOI":"10.1016\/j.jacc.2013.11.053"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. <i>Circ J<\/i> 2013; 77: 2209\u20132217.","DOI":"10.1253\/circj.CJ-13-0971"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H; on behalf of the CHART-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan: First report from the CHART-2 Study. <i>Circ J<\/i> 2011; 75: 823\u2013833.","DOI":"10.1253\/circj.CJ-11-0135"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, et al. Usefulness of combined risk stratification with heart rate and systolic blood pressure in the management of chronic heart failure: A report from the CHART-2 Study. <i>Circ J<\/i> 2013; 77: 2954\u20132962.","DOI":"10.1253\/circj.CJ-13-0725"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H, et al. Urinary albumin excretion in heart failure with preserved ejection fraction: An interim analysis of the CHART 2 study. <i>Eur J Heart Fail<\/i> 2012; 14: 367\u2013376.","DOI":"10.1093\/eurjhf\/hfs001"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, et al. Prognostic impact of nutritional status in asymptomatic patients with cardiac diseases: A report from the CHART-2 study. <i>Circ J<\/i> 2013; 77: 2318\u20132326.","DOI":"10.1253\/circj.CJ-13-0127"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sakata Y, Miyata S, Nochioka K, Miura M, Takada T, Tadaki S, et al. Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C\/D heart failure in Japan. <i>Circ J<\/i> 2014; 78: 428\u2013435.","DOI":"10.1253\/circj.CJ-13-1009"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol<\/i> 2013; 62: e147\u2013e239, doi:10.1016\/j.jacc.2013.05.019.","DOI":"10.1016\/j.jacc.2013.05.019"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from the Framingham heart study of the National Heart, Lung, And Blood Institute. <i>Circulation<\/i> 2009; 119: 3070\u20133077.","DOI":"10.1161\/CIRCULATIONAHA.108.815944"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. <i>Stat Med<\/i> 2010; 29: 2137\u20132148.","DOI":"10.1002\/sim.3854"},{"key":"29","unstructured":"29. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2014. http:\/\/www.R-project.org (accessed July 11, 2015)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relation of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham heart study. <i>Circulation<\/i> 2003; 107: 2920\u20132925.","DOI":"10.1161\/01.CIR.0000072767.89944.6E"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. <i>J Am Coll Cardiol<\/i> 2013; 61: 1894\u20131903.","DOI":"10.1016\/j.jacc.2013.01.069"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Braunwald E. Shattuck lecture: Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. <i>N Engl J Med<\/i> 1997; 337: 1360\u20131369.","DOI":"10.1056\/NEJM199711063371906"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kannel WB, Belanger AJ. Epidemiology of heart failure. <i>Am Heart J<\/i> 1991; 121: 951\u2013957.","DOI":"10.1016\/0002-8703(91)90225-7"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Rivero-Ayerza M, Scholte Op Reimer W, Lenzen M, Theuns DA, Jordaens L, Komajda M, et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: Results of the EuroHeart Failure Survey. <i>Eur Heart J<\/i> 2008; 29: 1618\u20131624.","DOI":"10.1093\/eurheartj\/ehn217"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Crijns HJ, Tjeerdsma G, de Kam PJ, Boomsma F, Gelder IC, Berg MP, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. <i>Eur Heart J<\/i> 2000; 21: 1238\u20131245.","DOI":"10.1053\/euhj.1999.2107"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. <i>J Am Coll Cardiol<\/i> 2005; 45: 712\u2013719.","DOI":"10.1016\/j.jacc.2004.10.068"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Am Heart J<\/i> 2006; 152: 86\u201392.","DOI":"10.1016\/j.ahj.2005.06.036"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, et al; on Behalf of the SUPPORT Trial Investigators. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. <i>Eur Heart J<\/i> 2015; 36: 915\u2013923.","DOI":"10.1093\/eurheartj\/ehu504"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Pena JM, ManFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: An exploratory analysis of the JUPITER trial. <i>Eur Heart J<\/i> 2012; 33: 531\u2013537.","DOI":"10.1093\/eurheartj\/ehr460"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, et al. Effects of rosuvastatin on atrial fibrillation occurrence: Ancillary results of the GISSI-HF trial. <i>Eur Heart J<\/i> 2009; 30: 2327\u20132336.","DOI":"10.1093\/eurheartj\/ehp357"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Macfarlane PW, Murray H, Sattar N, Stott DJ, Ford I, Buckley B, et al. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. <i>Europace<\/i> 2011; 13: 634\u2013639.","DOI":"10.1093\/europace\/eur016"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). <i>J Am Coll Cardiol<\/i> 2009; 54: 2023\u20132031.","DOI":"10.1016\/j.jacc.2009.08.020"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Adabag AS, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. <i>Am Heart J<\/i> 2007; 154: 1140\u20131145.","DOI":"10.1016\/j.ahj.2007.07.018"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee with the European Association of Echocardiography, a branch of the European Society of Cardiology. <i>J Am Soc Echocardiogr<\/i> 2005; 18: 1440\u20131463.","DOI":"10.1016\/j.echo.2005.10.005"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/1\/80_CJ-15-0783\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T21:07:00Z","timestamp":1498252020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/1\/80_CJ-15-0783\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-15-0783","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}